Work

Discovery of Pyrazoline Benzenesulfonamide Derivatives as Anticancer Agents: A Review

Year: 2025

Type: article

Abstract: Pyrazoline benzenesulfonamide derivatives represent a distinctive class of heterocyclic compounds that synergistically combine the pharmacological versatility of the pyrazoline scaffold with the enzyme-inhibitory prowess of benzenesulfonamide moieties. These hybrids have emerged as promising candidates in anticancer drug discovery. This review systematically examines various synthetic strategies employed to prepare these derivatives, including classical Claisen-Schmidt condensation as well as modern ultrasound- and microwave-assisted protocols. These methods facilitate efficient structural diversification, incorporating a wide range of heterocyclic and aromatic substituents such as morpholine, pyrazole, benzodioxole, tetrazole, and ferrocene. Biological evaluations, integrating both in vitro cytotoxicity assays and in silico molecular docking studies, were analyzed to elucidate the anticancer potential and mechanistic insights of these compounds, particularly their selective inhibition of tumor-associated enzymes such as matrix metalloproteinases (MMP-2, MMP-9), carbonic anhydrase isoforms (hCA IX, hCA XII), and cyclooxygenase-2 (COX-2). The results reveal that several derivatives exhibit potent antiproliferative activity across multiple cancer cell lines, including lung (A549), breast (MCF-7), cervical (HeLa), colon (COLO 205), and oral squamous carcinoma, demonstrating significant tumor selectivity and low toxicity toward normal cells. Structure-activity relationship analyses further underscore the critical influence of electronic substituents and their positioning on aromatic rings in modulating both efficacy and selectivity. These findings highlight the therapeutic potential of pyrazoline benzenesulfonamide derivatives and support the continued optimization of synthetic strategies and mechanistic studies to facilitate their development as effective anticancer agents capable of overcoming clinical challenges such as drug resistance and adverse side effects.

Source: Drug Design Development and Therapy

DOI: 10.2147/dddt.s562109

Authors: Dadang Hasyim, Ida Musfiroh, Rudi Hendra, Ezatul Kamarulzaman, Ritmaleni Ritmaleni, Muchtaridi Muchtaridi